Journal of Chinese Pharmaceutical Sciences ›› 2018, Vol. 27 ›› Issue (10): 675-685.DOI: 10.5246/jcps.2018.10.069

• Original articles • Previous Articles     Next Articles

A new compound W026B alleviates ischemic brain injury through inhibiting the production of inflammatory cytokines in pMCAO and tMCAO, and enhances the beneficial effect of tPA

Ye Zhang1, Danping Zheng1, Mengyang Shui1, Ye Liu2, Xiaoyan Liu1*, Yinye Wang1*   

  1. 1. Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
    2. Beijing Honghui New Medical Technology Co.Ltd.; Beijing Daxing Biological Medicine Industry Base, Beijing 102600, China
  • Received:2018-03-25 Revised:2018-06-25 Online:2018-10-30 Published:2018-09-10
  • Contact: Tel.: +86-010-82802652, E-mail:;
  • Supported by:

    National Natural Science Foundation of China (Grant No. 81573333, 81503060).


Neruoprotection is considered as one of important therapeutic approaches for ischemic stroke. Inflammation plays an important role in the pathogenesis of ischemic stroke, and the inhibition of inflammation in the ischemic brain tissue may provide neuroprotective effect. In this study, we observed the influence of permanent middle cerebral artery occlussion (pMCAO) and transient MCAO (tMCAO) on NF-κB level and production of several inflammatory cytokines in injured hemisphere in mice, investigated the regulative effect of a new compound W026B on these influences in the two MCAO models. In pMCAO model, 10 μg/kg and 100 μg/kg of W026B (i.v.) significantly reduced infarct volumes, 100 μg/kg of W026B significantly decreased neurologic deficit scores and brain water contents, and 10 μg/kg and 100 μg/kg of W026B reduced Evans blue exudation from ischemic brain tissue. The level of NF-κB was elevated by 17.6 times in injured hemisphere, and the levels of TNF-α, IL-1β and IL-17 were elevated by 2.3 times, 2.2 times and 3.8 times compared with the sham operation group, respectively, 100 μg/kg of W026B significantly reduced these inflammatory cytokines. In tMCAO model, the elevation of NF-κB, TNF-α, IL-1β and IL-17 was 2.3 times, 1.4 times, 1.5 times and 1.4 times compared with the sham operation group, respectively. Moreover, 100 μg/kg of W026B significantly decreased the levels of these inflammatory cytokines. In embolic MCAO mice model, W026B alone significantly reduced infarct volumes, and combined application with tPA further reduced infarct volume. In conclusion, W026B displayed significant protecive effect on three brain ischemia models. It could protect brain against injury induced by ischmia and ischemia-reperfusion through inhibiting the production of NF-κB, TNF-α, IL-1β and IL-17. These results suggest that W026B has a value for further study.  

Key words: Ischemia-reperfusion, NF-κB, Proinflammatory cytokines, W026B

CLC Number: